RSR13 Investigator Presented With National Tumor Foundation Research Award At Society for Neuro-Oncology Annual Meeting
November 15 2003 - 1:00PM
PR Newswire (US)
RSR13 Investigator Presented With National Tumor Foundation
Research Award At Society for Neuro-Oncology Annual Meeting
KEYSTONE, Colo., Nov. 15 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. announced today that John H. Suh, M.D., Clinical
Director, Radiation Oncology, Brain Tumor Institute at the
Cleveland Clinic, has received the National Tumor Foundation
Clinical Research Award at the Eighth Annual Meeting of The Society
for Neuro-Oncology in Keystone, Colorado, for his leading role in
the pivotal Phase 3 clinical trial of Allos Therapeutics'
investigational drug RSR13 (efaproxaril). Dr. Suh co-chaired the
randomized, open-label study that compared standard whole brain
radiation therapy (WBRT) with supplemental oxygen with or without
RSR13 in patients with brain metastases. RSR13 is an
investigational radiation sensitizer being developed by Allos
Therapeutics that facilitates the release of oxygen from hemoglobin
to hypoxic (oxygen-deprived) tumor tissues, making radiation
therapy more effective. "The National Brain Tumor Foundation is
pleased to honor Dr. Suh with this award. His groundbreaking work
suggests that the survival of patients with brain metastases can be
extended and gives hope to patients for whom there are few
treatment options," said Janis C. Brewer, Executive Director,
National Brain Tumor Foundation. "The National Brain Tumor
Foundation supports the development of better treatments for people
who suffer from brain metastases and applauds Dr. Suh and his
colleagues for their contributions to this important area of cancer
research." Dr. Suh stated: "I am very gratified to receive this
award in recognition of our clinical research with RSR13. Treatment
of brain metastases is an exciting and evolving field and our work
with RSR13 demonstrates that bringing together tumor biology and
radiotherapy can yield promising new therapies. We are very
encouraged by these favorable results and hope to see this product
advance to treat patients who have limited therapeutic options."
Previously reported results of the RSR13 Phase 3 trial show the
risk of death in all patients treated was reduced by 22 percent
when RSR13 was added to whole brain radiation therapy in patients
with brain metastases. Among breast cancer patients, RSR13's
therapeutic benefit was even more potent and showed a near doubling
of the median survival (4.57 vs 8.67 months). "We congratulate Dr.
Suh and his colleagues in receiving this award, which recognizes
their outstanding contributions to the treatment of patients with
brain metastases," said Michael E. Hart, President and Chief
Executive Officer of Allos Therapeutics. Allos Therapeutics, Inc.
is currently submitting a rolling New Drug Application (NDA) to the
U.S. Food and Drug Administration (FDA) for RSR13 for the treatment
of patients with breast cancer that has metastasized to the brain.
The company expects to complete its NDA submission in December
2003. About Brain Metastases in Breast Cancer Patients
Approximately 200,000 women and 1,300 men will be diagnosed with
breast cancer in the United States in 2003. Approximately 20-to-30
percent of these breast cancer patients will develop brain
metastases. The most common type of brain cancer, brain metastases
are tumors that have spread to the brain from a malignant tumor in
another part of the body. This condition occurs in approximately
one out of five cancer patients, most often in patients with breast
cancer or non-small cell lung cancer. There are approximately
175,000 annual cases of brain metastases in the U.S. Standard
whole-brain radiation is the primary palliative therapy for
treating patients with brain metastases and has been shown to
prevent or reduce complications and to increase survival. About
National Brain Tumor Foundation The National Brain Tumor Foundation
is a nationwide non-profit organization serving people whose lives
have been affected by brain tumors. They are dedicated to promoting
a cure for brain tumors, improving the quality of life and giving
hope to the brain tumor community by funding meaningful research
and providing patient resources, timely information and education.
About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a
biopharmaceutical company focused on developing and commercializing
innovative drugs for improving cancer treatments. The company's
lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen
deprived) tumor tissues and enhance the efficacy of standard
radiation therapy. In addition, Allos is developing PDX, a novel
small molecule cytotoxic injectable antifolate (DHFR inhibitor)
being developed for non-small cell lung cancer, mesothelioma and
non-Hodgkin's lymphoma. For more information, please visit the
company's web site at: http://www.allos.com/. This announcement
contains forward-looking statements that involve risks and
uncertainties. Future events may differ materially from those
discussed herein due to a number of factors, including, but not
limited to, risks and uncertainties related to the company's
ability to complete the submission of its NDA to the FDA on
schedule and in accordance with regulatory requirements, to
adequately demonstrate the safety and efficacy of RSR13 for use as
a radiation sensitizer in the treatment of breast cancer that has
metastasized to the brain and any other type of cancer, and its
ability to obtain regulatory approval for RSR13, as well as other
risks and uncertainties detailed from time to time in the company's
SEC filings, including its Annual Report on Form 10-K for the year
ended December 31, 2002. All forward-looking statements are based
on information currently available to the company on the date
hereof, and the company assumes no responsibility to update such
statements. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Monique
M. Greer VP, Corporate Communications and Investor Relations,
+1-720-540-5241 (direct), ; or Lazar Partners Limited (media), Fern
Lazar, +1-/First Call Analyst: Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024